Recent developments focus on regulatory progress and financing activities.

• In March 2024, United Health Products submitted a full FDA Premarket Approval application for CelluSTAT; the FDA issued a Deficiencies Letter in June 2024 with approximately 40 comments and requests for additional data [S1].
• The FDA conducted an inspection of the company’s 2019 clinical study records in late 2024, resulting in a Warning Letter in March 2025 citing five regulatory violations [S1].
• The company responded with corrective actions and engaged an external monitor; FDA provided feedback and requested further audits and monitoring, including a Good Clinical Practices audit expected to complete by July 2026 [S1].
• United Health Products is collaborating with the FDA and potential partners to conduct a new pivotal IDE study with an approved substitute Sponsor [S1].
• The company entered into a loan agreement with Alumni Capital LP in December 2025, receiving net proceeds of $250,000 evidenced by a senior convertible promissory note maturing December 31, 2026 [S1].
• The company also entered into an Any Market Purchase Agreement with Alumni Capital for up to $4 million in common stock sales through December 31, 2027, and issued warrants to Alumni [S1].
• There is no assurance that the FDA PMA application will be approved or that the company will successfully commercialize its product [S1].
• United Health Products provided a public update on its PMA application progress in November 2024 [N1].

United Health Products has developed a patented hemostatic gauze with unique properties that differentiate it from competitors, including hypoallergenic composition and a gel-forming mechanism that facilitates coagulation monitoring. The company’s ongoing efforts to obtain FDA Premarket Approval for Class III surgical use could open access to premium-priced surgical markets with limited competition. Interest from established medical technology companies in potential partnerships or acquisition discussions suggests strategic value in the product and technology. The company’s contract manufacturing with FDA-certified suppliers and multiple registered trademarks support scalability and brand recognition. Recent financing arrangements provide capital to support regulatory and operational activities.

United Health Products faces significant regulatory hurdles, including a Warning Letter from the FDA citing violations in its 2019 clinical study and ongoing requirements for corrective actions and audits. The timing and outcome of FDA approval remain uncertain, with no assurance of success. The company has no current revenue and operates at a net loss, with liquidity challenges indicated by a very low current ratio and cash ratio. The company is dependent on additional financing and strategic partnerships, which may not materialize on favorable terms or at all. Competition from large, well-resourced wound care companies may limit market penetration. The company’s stock is a penny stock with limited market liquidity, which may affect investor interest and capital raising ability.

United Health Products’ moat is primarily based on its patented CelluSTAT hemostatic gauze technology, which is chemically treated cellulose derived from cotton and protected by U.S. patents through 2029. The product’s unique features include hypoallergenic composition, absence of chemical additives or animal products, and a gel-forming mechanism that allows monitoring of coagulation without damaging tissue. The company’s focus on Class III surgical markets, which have fewer competitors and higher regulatory barriers, may provide a competitive advantage if regulatory approvals are obtained. However, the company faces significant competition from large, well-capitalized wound care companies with established product lines and distribution networks. The moat is thus contingent on successful regulatory approval and effective commercialization partnerships.

• Regulatory Approval Risk: The company’s business strategy depends on obtaining FDA Premarket Approval for Class III surgical use of CelluSTAT. The FDA has identified deficiencies and violations in the clinical study, and there is no assurance the PMA will be approved.
• Financial and Liquidity Risk: United Health Products has no revenue, operates at a net loss, and has a working capital deficit with a current ratio of 0.03 as of December 31, 2025. The company relies on financing arrangements to fund operations, which may not be available or sufficient.
• Commercialization and Market Acceptance Risk: The company has paused commercial activities pending regulatory approval and does not currently have commercial partnerships. Market acceptance of CelluSTAT and successful penetration into target segments are uncertain.
• Competitive Risk: The wound care market is dominated by large, established companies with greater resources. United Health Products faces competition on product performance, price, service, and distribution.
• Operational Risk: The company depends on contract manufacturing and third-party suppliers. Disruptions in supply chain or manufacturing could adversely affect product availability and business operations.

• United Health Products, Inc. develops, manufactures, and markets a patented hemostatic gauze called CelluSTAT for healthcare and wound care sectors [S1].
• CelluSTAT is derived from cotton, designed to absorb exudate/drainage from superficial wounds and help control bleeding [S1].
• The company is seeking FDA Premarket Approval (PMA) for CelluSTAT for U.S. Class III and European CE Mark human surgical markets [S1].
• CelluSTAT received FDA 510(k) approval in 2012 for external or superficial bleeding use [S1].
• The product is a flexible, silk-like gauze that converts to a translucent gel upon contact with blood, allowing monitoring of coagulation and maintaining neutral pH to avoid tissue damage [S1].
• CelluSTAT contains no chemical additives, thrombin, collagen, or animal-derived products and is hypoallergenic [S1].
• The company submitted a full PMA application in March 2024; FDA issued a Deficiencies Letter in June 2024 with about 40 comments and requests for additional data [S1].
• FDA conducted a Bioresearch Monitoring Program inspection in late 2024, resulting in Inspectional Observations and a Warning Letter in March 2025 citing five violations related to the 2019 clinical study conduct [S1].
• United Health Products responded with Corrective and Preventative Actions (CAPAs) and engaged an external monitor; FDA provided feedback and requested further audits and monitoring [S1].
• The company is collaborating with FDA and potential partners to conduct a new pivotal IDE study with a substitute Sponsor approved by FDA [S1].
• The timing to resolve the FDA Warning Letter is uncertain, and there is no assurance the PMA application will be approved [S1].
• The company’s primary strategy focuses on the Class III human surgical market due to limited competition and premium pricing [S1].
• United Health Products does not intend to commercialize independently long term; it is considering sale, merger, or commercial partnerships with established market participants [S1].
• Manufacturing is outsourced to FDA-certified suppliers with quality control; packaging and sterilization occur in the U.S. [S1].
• The company holds patents protecting its hemostatic gauze technology through 2029 and has registered trademarks for multiple product formats including CelluSTAT [S1].
• The wound care market is concentrated among large companies like Baxter, Becton Dickinson, Johnson & Johnson (Ethicon), Teleflex, and 3M, which have greater resources [S1].
• United Health Products had no revenue and a net loss of $2,669,348 for the year ended December 31, 2025 [S1].
• As of December 31, 2025, the company had cash and equivalents of $31,955 and current assets of $105,392 against current liabilities of $3,943,149, resulting in a current ratio of 0.03 and cash ratio of 0.01, indicating liquidity challenges [S1].
• The company entered into a loan agreement with Alumni Capital LP in December 2025, receiving net proceeds of $250,000 evidenced by a senior convertible promissory note maturing December 31, 2026 [S1].
• The company also entered into an Any Market Purchase Agreement with Alumni Capital for up to $4 million in common stock sales through December 31, 2027, and issued warrants to Alumni [S1].
• United Health Products’ common stock trades on the OTCQB and is considered a penny stock, which may limit liquidity and market interest [S1].
• The company’s business and financial condition are subject to risks including ongoing operating losses, regulatory approval uncertainty, financing needs, competitive pressures, and dependence on commercial partnerships [S1].
• Recent news includes an update on the PMA application progress and FDA interactions [N1].
• There is no direct involvement of United Health Products in the FTC lawsuit against CVS Health, Cigna, and United Health Group regarding insulin prices; this is unrelated to United Health Products [N2].